Moolec Science (MLEC) Other Accumulated Expenses (2022)

Moolec Science (MLEC) reported Other Accumulated Expenses of $838117.0 for Q4 2022, up 71472.76% sequentially from $1171.0 in Q2 2022.

Moolec Science (MLEC) Other Accumulated Expenses (2022) Analysis & Trends

Moolec Science (MLEC) has 1 years of Other Accumulated Expenses data on file, last reported at $838117.0 in Q4 2022.

For the quarter ending Q4 2022, Other Accumulated Expenses changed N/A year-over-year to $838117.0; the trailing twelve-month figure through Dec 2022 stood at $838117.0 (changed N/A YoY), and the FY2022 full-year result was $1171.0, changed N/A from the prior year.
Other Accumulated Expenses grew to $838117.0 in Q4 2022, from $1171.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $838117.0 in Q4 2022 to a low of $1171.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,561.01 Bn	66,560.72 Bn	-
2	Nanobiotix	1,911.11 Bn	1,911.05 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	467.81 Bn	463.02 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.92 Bn	115.68 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.28 Bn	61.53 Bn	3.31 Bn
7	Belite Bio	62.88 Bn	62.88 Bn	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.53 Bn	34.52 Bn	959.66 Mn
10	Moolec Science	5.21 Bn	5.21 Bn	-

Download Data

Date	Value
Dec 31, 2022	838,117.00
Jun 30, 2022	1,171.00